Last Updated: November 9, 2026

CLINICAL TRIALS PROFILE FOR NIRAPARIB TOSYLATE

« Back to Dashboard

All Clinical Trials for NIRAPARIB TOSYLATE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04030559 ↗	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	Recruiting	Janssen, LP	Phase 2	2020-02-25	This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT04030559 ↗	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	Recruiting	National Cancer Institute (NCI)	Phase 2	2020-02-25	This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT04030559 ↗	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	Recruiting	University of California, Davis	Phase 2	2020-02-25	This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for NIRAPARIB TOSYLATE

Condition Name

Chart
Table

Condition Name for NIRAPARIB TOSYLATE
Intervention	Trials
DNA Repair Gene Mutation	1
Unilateral Breast Carcinoma	1
Multifocal Breast Carcinoma	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for NIRAPARIB TOSYLATE
Intervention	Trials
Leiomyosarcoma	1
Carcinoma	1
Breast Neoplasms	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for NIRAPARIB TOSYLATE

Trials by Country

Map
Table

Trials by Country for NIRAPARIB TOSYLATE
Location	Trials
United States	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for NIRAPARIB TOSYLATE
Location	Trials
Ohio	1
Oregon	1
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for NIRAPARIB TOSYLATE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for NIRAPARIB TOSYLATE
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for NIRAPARIB TOSYLATE
Clinical Trial Phase	Trials
Recruiting	2
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NIRAPARIB TOSYLATE

Sponsor Name

Chart
Table

Sponsor Name for NIRAPARIB TOSYLATE
Sponsor	Trials
National Cancer Institute (NCI)	2
Eli Lilly and Company	1
GlaxoSmithKline	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for NIRAPARIB TOSYLATE
Sponsor	Trials
Other	4
Industry	3
NIH	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.